Rheumatology Medical News about Glucosamine sulfate, Knee osteoarthritis

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Rapid correction of low vitamin D status in nursing home residents

3. 2008 Exclusive Survey—Earnings: Good news for primary care income

4. Medicare pay-for-reporting effort draws fire from frustrated doctors

5. Allopurinol-induced recurrent dress syndrome: Pathophysiology and treatment

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

The efficacy and tolerability of glucosamine sulfate in the treatment of knee osteoarthritis: A randomized, double-blind, placebo-controlled trial
Current Therapeutic Research, 07/31/09

Giordano N et al. – Study reports that glucosamine sulfate (GS) 1500 mg QD PO for 12 wks was associated with statistically significant reductions in pain and improvements in functioning, with decreased analgesic consumption, compared with baseline and placebo in pts with knee osteoarthritis (OA). A carryover effect was detected after treatment ended.

Methods

Aim was to assess the efficacy and tolerability of GS in the treatment of knee OA
Consecutive outpatients (n=60); affected by primary monolateral or bilateral knee OA, randomized to:
- GS 1500 mg QD for 12 weeks, (n=30) and
- Placebo QD for 12 wks (n=30)
Treatment period was followed by a 12-wk treatment-free observation phase
Each patient was examined at baseline and at wks 4, 8, 12, 16, 20, and 24
Primary efficacy criteria: pain at rest and during movement, assessed on VAS of 0-100 mm
Secondary criteria: WOMAC index for total pain score (W-TPS), total stiffness score (W-TSS), and total physical function score (W-TPFS)
VAS, W-TPS, W-TSS, and W-TPFS were evaluated at baseline and at wks 4, 8, 12, 16, 20, and 24
Analgesic drug consumption (ie, acetaminophen or NSAIDs) was also assessed

Results

Patient demographics were similar in the GS and placebo groups
56/60 pts completed the study (28 with GS and 28 who received placebo)
An improvements in symptomatic knee OA were observed, as measured by differences in resting pain at wks 8, 12, and 16 and in pain during movement at wks 12 and 16
W-TPS was lower with GS than placebo at wks 8, 12, and 16, and at wk 20
W-TSS was also lower with GS than placebo at wks 8, 12, 16, and 20
W-TPFS was lower with GS than placebo at wks 8, 12, 16, and 20
Drug consumption was lower in the GS group vs placebo group at wks 8, 12, 16, and 20
Incidence of AEs was 36.7% with GS and 40.0% with placebo

<< Previous
Currents concepts on the immunopathology of amyloidosis

Next >>
Factors affecting the quality of life in patients with...